This clinical study population will consist of a minimum of 100, and up to 120 subjects with insulin-requiring diabetes mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) therapy; equal number of subjects will be enrolled among each therapy group. It is desirable to have a similar distribution of baseline A1C in each study group.